Clinical Trial Update: Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab with or without carboplatin in estrogen receptor-negative, progesterone receptor-negative metastatic breast cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Carboplatin (Paraplatin) (carboplatin)
• ERBITUX (cetuximab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-28